Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions

Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are a promising second‐line treatment strategy for type 2 diabetes mellitus (T2DM) with a developing landscape of both beneficial cardio‐ and nephroprotective properties and emerging adverse drug reactions (ADRs) including diabetic ketoacidosis (DK...

Descripción completa

Detalles Bibliográficos
Autores principales: Matharu, Karan, Chana, Kiran, Ferro, Charles J., Jones, Alan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480305/
https://www.ncbi.nlm.nih.gov/pubmed/34586753
http://dx.doi.org/10.1002/prp2.867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480305/
https://www.ncbi.nlm.nih.gov/pubmed/34586753
http://dx.doi.org/10.1002/prp2.867

Ejemplares similares